Understanding the Mechanism of Insulin and Insulin-like Growth Factor (IGF) Receptor Activation by IGF-II

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Dec 6

PMID 22140443

Citations 33

Authors

Clair L Alvino

Shee Chee Ong

Kerrie A McNeil

Carlie Delaine

Grant W Booker

John C Wallace

Briony E Forbes

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor-II (IGF-II) promotes cell proliferation and survival and plays an important role in normal fetal development and placental function. IGF-II binds both the insulin-like growth factor receptor (IGF-1R) and insulin receptor isoform A (IR-A) with high affinity. Interestingly both IGF-II and the IR-A are often upregulated in cancer and IGF-II acts via both receptors to promote cancer proliferation. There is relatively little known about the mechanism of ligand induced activation of the insulin (IR) and IGF-1R. The recently solved IR structure reveals a folded over dimer with two potential ligand binding pockets arising from residues on each receptor half. Site-directed mutagenesis has mapped receptor residues important for ligand binding to two separate sites within the ligand binding pocket and we have recently shown that the IGFs have two separate binding surfaces which interact with the receptor sites 1 and 2.

Methodology/principal Findings: In this study we describe a series of partial IGF-1R and IR agonists generated by mutating Glu12 of IGF-II. By comparing receptor binding affinities, abilities to induce negative cooperativity and potencies in receptor activation, we provide evidence that residue Glu12 bridges the two receptor halves leading to receptor activation.

Conclusions/significance: This study provides novel insight into the mechanism of receptor binding and activation by IGF-II, which may be important for the future development of inhibitors of its action for the treatment of cancer.

Citing Articles

Hypoglycemia in Children: Major Endocrine-Metabolic Causes and Novel Therapeutic Perspectives.

Quarta A, Iannucci D, Guarino M, Blasetti A, Chiarelli F Nutrients. 2023; 15(16).

PMID: 37630734 PMC: 10459037. DOI: 10.3390/nu15163544.

Unveiling Diabetes: Categories, Genetics, Diagnostics, Treatments, and Future Horizons.

Alam A, Dhoundiyal S, Ahmad N, Koteswara Rao G Curr Diabetes Rev. 2023; 20(4):e180823219972.

PMID: 37594107 DOI: 10.2174/1573399820666230818092958.

The crosstalk within the breast tumor microenvironment in type II diabetes: Implications for cancer disparities.

Ennis C, Llevenes P, Qiu Y, Dries R, Denis G Front Endocrinol (Lausanne). 2022; 13:1044670.

PMID: 36531496 PMC: 9751481. DOI: 10.3389/fendo.2022.1044670.

Molecular basis for the role of disulfide-linked αCTs in the activation of insulin-like growth factor 1 receptor and insulin receptor.

Li J, Wu J, Hall C, Bai X, Choi E Elife. 2022; 11.

PMID: 36413010 PMC: 9731570. DOI: 10.7554/eLife.81286.

Trends in insulin resistance: insights into mechanisms and therapeutic strategy.

Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H Signal Transduct Target Ther. 2022; 7(1):216.

PMID: 35794109 PMC: 9259665. DOI: 10.1038/s41392-022-01073-0.

References

Renehan A, Brennan B . Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008; 22(4):639-57. DOI: 10.1016/j.beem.2008.08.011. View

Pietrzkowski Z, Lammers R, Carpenter G, Soderquist A, Limardo M, Phillips P . Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 1992; 3(4):199-205. View

De Meyts P, URSO B, Christoffersen C, Shymko R . Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. Ann N Y Acad Sci. 1995; 766:388-401. DOI: 10.1111/j.1749-6632.1995.tb26688.x. View

Schwartz G, Burke G, KATSOYANNIS P . A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A. 1987; 84(18):6408-11. PMC: 299085. DOI: 10.1073/pnas.84.18.6408. View

McKern N, Lawrence M, Streltsov V, Lou M, Adams T, Lovrecz G . Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature. 2006; 443(7108):218-21. DOI: 10.1038/nature05106. View

Gallagher E, LeRoith D . The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 2010; 21(10):610-8. PMC: 2949481. DOI: 10.1016/j.tem.2010.06.007. View

Whittaker J, Sorensen H, Gadsboll V, Hinrichsen J . Comparison of the functional insulin binding epitopes of the A and B isoforms of the insulin receptor. J Biol Chem. 2002; 277(49):47380-4. DOI: 10.1074/jbc.M208371200. View

Taniguchi C, Emanuelli B, Kahn C . Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7(2):85-96. DOI: 10.1038/nrm1837. View

Gicquel C, Le Bouc Y . Hormonal regulation of fetal growth. Horm Res. 2006; 65 Suppl 3:28-33. DOI: 10.1159/000091503. View

10.

Sadick M . Kinase Receptor Activation (KIRA): a rapid and accurate alternative to endpoint bioassays. Dev Biol Stand. 1999; 97:121-33. View

11.

Wells J . Systematic mutational analyses of protein-protein interfaces. Methods Enzymol. 1991; 202:390-411. DOI: 10.1016/0076-6879(91)02020-a. View

12.

Milner S, Francis G, Wallace J, Magee B, Ballard F . Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties. Biochem J. 1995; 308 ( Pt 3):865-71. PMC: 1136804. DOI: 10.1042/bj3080865. View

13.

Denley A, Bonython E, Booker G, Cosgrove L, Forbes B, Ward C . Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol. 2004; 18(10):2502-12. DOI: 10.1210/me.2004-0183. View

14.

Surinya K, Forbes B, Occhiodoro F, Booker G, Francis G, Siddle K . An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem. 2007; 283(9):5355-63. DOI: 10.1074/jbc.M707054200. View

15.

Christoffersen C, Bornfeldt K, Rotella C, Gonzales N, Vissing H, Shymko R . Negative cooperativity in the insulin-like growth factor-I receptor and a chimeric IGF-I/insulin receptor. Endocrinology. 1994; 135(1):472-5. DOI: 10.1210/endo.135.1.8013387. View

16.

Francis G, Aplin S, Milner S, McNeil K, Ballard F, Wallace J . Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993; 293 ( Pt 3):713-9. PMC: 1134424. DOI: 10.1042/bj2930713. View

17.

Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R . Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009; 30(6):586-623. DOI: 10.1210/er.2008-0047. View

18.

Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C . Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000; 49(6):999-1005. DOI: 10.2337/diabetes.49.6.999. View

19.

Gauguin L, Delaine C, Alvino C, McNeil K, Wallace J, Forbes B . Alanine scanning of a putative receptor binding surface of insulin-like growth factor-I. J Biol Chem. 2008; 283(30):20821-9. PMC: 3258947. DOI: 10.1074/jbc.M802620200. View

20.

Ulanet D, Ludwig D, Kahn C, Hanahan D . Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010; 107(24):10791-8. PMC: 2890766. DOI: 10.1073/pnas.0914076107. View